NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.

NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.